Breaking News Instant updates and real-time market news.

HALO

Halozyme

$17.16

0.33 (1.96%)

04:55
04/11/19
04/11
04:55
04/11/19
04:55

Halozyme management to meet with JPMorgan

Meetings to be held in Europe on April 9-11 hosted by JPMorgan.

  • 11

    Apr

  • 02

    May

  • 22

    May

  • 23

    May

HALO Halozyme
$17.16

0.33 (1.96%)

11/27/18
JEFF
11/27/18
NO CHANGE
Target $9
JEFF
Underperform
Jefferies still sees low likelihood of success for Halozyme's PEGPH20
Following the announced change in the Phase 3 endpoint, Jefferies analyst Eun Yang continues to view probability for success of Halozyme Therapeutics's PEGPH20 in pancreatic cancer as low. The change in the HALO-301 endpoint/data analysis "dampens our confidence further," Yang tells investors in a research note. HALO-301 is a phase 3 global, randomized, double-blind placebo controlled clinical trial evaluating investigational new drug PEGPH20 as a first-line therapy for potential treatment of patients with metastatic pancreas cancer. The analyst remains cautious on Halozyme shares with an Underpeform rating and $9 price target.
11/27/18
JMPS
11/27/18
NO CHANGE
Target $21
JMPS
Outperform
Halozyme Phase 3 trial amendment makes sense, says JMP Securities
After Halozyme announced that it is amending the design of the Phase 3 trial evaluating PEGPH20 in front-line pancreatic cancer to make overall survival the sole primary endpoint, JMP Securities analyst Jason Butler said he thinks the change makes sense and is neutral to his thesis. While the change pushes out first results by about 6-9 months, the "outcome will be definitive," said Butler, who reiterates an Outperform rating and $21 price target on Halozyme shares.
01/11/19
WELS
01/11/19
NO CHANGE
WELS
Outperform
Halozyme undervalued relative to 'de -risked' assets, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Overweight rating on Halozyme Therapeutics following this week's update and 2019 outlook. The analyst continues to view the company as undervalued relative to its "highly de -risked" lead Enhanze assets. He sees "significant option value" to the broader Enhanze opportunity and PEGPH20 data.
02/05/19
PIPR
02/05/19
NO CHANGE
Target $161
PIPR
Overweight
Piper says argenx cusatuzumab study could enable registration if responses hold
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $161 price target on argenx (ARGX) after the company announced a collaboration agreement with Halozyme (HALO). In a research note to investors, Tenthoff says that an ongoing Phase II study of cusatuzumab, which was licensed to Janssen (JNJ) after demonstrating a 92% response rate in AML at ASH, could enable registration if responses hold. The company will host an R&D Day in NYC on May 16 to introduce ARGX-117 and also expects the company will introduce ARGX-118.

TODAY'S FREE FLY STORIES

PM

Philip Morris

$85.49

-0.71 (-0.82%)

07:01
04/18/19
04/18
07:01
04/18/19
07:01
Earnings
Philip Morris reports Q1 adjusted EPS $1.09, consensus 97c »

Reports Q1 revenue $6.8B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 01

    May

  • 06

    May

TRV

Travelers

$135.89

-2.48 (-1.79%)

07:01
04/18/19
04/18
07:01
04/18/19
07:01
Hot Stocks
Travelers raises quarterly dividend 6.5% to 82c per share »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

LVS

Las Vegas Sands

$67.90

-0.205 (-0.30%)

, WYNN

Wynn Resorts

$143.35

-1.37 (-0.95%)

07:01
04/18/19
04/18
07:01
04/18/19
07:01
Recommendations
Las Vegas Sands, Wynn Resorts, Melco Resorts & Entertainment analyst commentary  »

Las Vegas Sands price…

LVS

Las Vegas Sands

$67.90

-0.205 (-0.30%)

WYNN

Wynn Resorts

$143.35

-1.37 (-0.95%)

MLCO

Melco Resorts & Entertainment

$26.43

0.52 (2.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 16

    May

  • 29

    May

INN

Summit Hotel Properties

$11.64

0.01 (0.09%)

07:00
04/18/19
04/18
07:00
04/18/19
07:00
Hot Stocks
Summit Hotel Properties sells 6 hotels for $135M »

Summit Hotel Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 16

    May

  • 16

    May

07:00
04/18/19
04/18
07:00
04/18/19
07:00
General news
European stock markets are trading mixed, »

European stock markets…

TRV

Travelers

$135.89

-2.48 (-1.79%)

06:59
04/18/19
04/18
06:59
04/18/19
06:59
Hot Stocks
Travelers reports consolidated combined ratio of 93.7% »

Reports underlying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

TRV

Travelers

$135.89

-2.48 (-1.79%)

06:58
04/18/19
04/18
06:58
04/18/19
06:58
Hot Stocks
Travelers reports book value per share $92.94, up 7% from year-end 2018 »

Reports adjusted book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

TRV

Travelers

$135.89

-2.48 (-1.79%)

06:57
04/18/19
04/18
06:57
04/18/19
06:57
Hot Stocks
Breaking Hot Stocks news story on Travelers »

Travelers raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

CTG

Computer Task Group

$4.27

0.02 (0.47%)

06:57
04/18/19
04/18
06:57
04/18/19
06:57
Earnings
Computer Task Group backs FY19 non-GAAP EPS view 30c-40c, consensus 33c »

Backs FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

SNAP

Snap

$11.75

0.08 (0.69%)

06:57
04/18/19
04/18
06:57
04/18/19
06:57
Downgrade
Snap rating change  »

Snap downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

TRV

Travelers

$135.89

-2.48 (-1.79%)

06:57
04/18/19
04/18
06:57
04/18/19
06:57
Earnings
Travelers reports Q1 core EPS $2.83, consensus $2.74 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

FSLR

First Solar

$60.70

0.17 (0.28%)

06:57
04/18/19
04/18
06:57
04/18/19
06:57
Recommendations
First Solar analyst commentary  »

First Solar should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 17

    May

PPG

PPG

$117.39

-1.01 (-0.85%)

06:57
04/18/19
04/18
06:57
04/18/19
06:57
Earnings
PPG backs FY19 adjusted EPS growth 7%-10%, consensus $6.24 »

"More broadly, we…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 18

    Apr

CTG

Computer Task Group

$4.27

0.02 (0.47%)

06:56
04/18/19
04/18
06:56
04/18/19
06:56
Earnings
Computer Task Group reports Q1 non-GAAP EPS 6c, consensus 6c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

PPG

PPG

$117.39

-1.01 (-0.85%)

06:54
04/18/19
04/18
06:54
04/18/19
06:54
Hot Stocks
PPG CEO says Q1 operating margins 'were higher than the prior year' »

"First quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 18

    Apr

PPG

PPG

$117.39

-1.01 (-0.85%)

06:53
04/18/19
04/18
06:53
04/18/19
06:53
Hot Stocks
PPG says committed to finalizing strategic review be end of second quarter »

The company continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 18

    Apr

IRBT

iRobot

$129.26

-0.74 (-0.57%)

06:52
04/18/19
04/18
06:52
04/18/19
06:52
Recommendations
iRobot analyst commentary  »

iRobot price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

PPG

PPG

$117.39

-1.01 (-0.85%)

06:52
04/18/19
04/18
06:52
04/18/19
06:52
Earnings
PPG sees Q2 EPS $1.76-$1.86, consensus $1.86 »

"As we look ahead to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 18

    Apr

MNK

Mallinckrodt

$19.12

-2.51 (-11.60%)

06:52
04/18/19
04/18
06:52
04/18/19
06:52
Hot Stocks
Mallinckrodt announces results from gNO with EVLP study »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 07

    May

PPG

PPG

$117.39

-1.01 (-0.85%)

06:51
04/18/19
04/18
06:51
04/18/19
06:51
Earnings
PPG reports Q1 adjusted EPS $1.38, consensus $1.21 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 18

    Apr

LULU

Lululemon

$171.19

2.28 (1.35%)

06:51
04/18/19
04/18
06:51
04/18/19
06:51
Conference/Events
Lululemon to host analyst day »

Analyst day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

SON

Sonoco

$60.98

-0.235 (-0.38%)

06:49
04/18/19
04/18
06:49
04/18/19
06:49
Earnings
Sonoco raises FY19 base EPS view to $3.52-$3.62 from $3.47-$3.57 »

Consensus for FY19 EPS is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 07

    May

  • 18

    Jul

  • 17

    Oct

DOV

Dover

$96.81

-0.66 (-0.68%)

06:49
04/18/19
04/18
06:49
04/18/19
06:49
Earnings
Breaking Earnings news story on Dover »

Dover backs FY19 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 02

    May

VRAY

ViewRay

$7.26

-0.16 (-2.16%)

06:49
04/18/19
04/18
06:49
04/18/19
06:49
Hot Stocks
ViewRay announces Minouge Medical as Canadian distributor of MRIdian »

ViewRay announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

NICE

Nice

$130.90

2.04 (1.58%)

, VRNT

Verint

$60.20

-1.49 (-2.42%)

06:48
04/18/19
04/18
06:48
04/18/19
06:48
Upgrade
Nice, Verint rating change  »

JPMorgan upgrades Nice to…

NICE

Nice

$130.90

2.04 (1.58%)

VRNT

Verint

$60.20

-1.49 (-2.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.